Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in Pancreatic Cancer with DNA Repair Deficiencies
NCT03601923Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in pancreatic cancer (PC), sponsored by Dana-Farber Cancer Institute. Started Aug 2018; status: completed.
02
Drugs
niraparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03601923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03601923.